Axsome's Drug Candidate for Alzheimer's Disease Agitation Meets Primary Endpoint in Phase 3 Trial, Falls Short in Another
Axsome's Drug Candidate for Alzheimer's Disease Agitation Meets Primary Endpoint in Phase 3 Trial, Falls Short in Another
Axsome針對阿爾茨海默病激動症的藥物候選在三期試驗中達到主要終點，但在另一個方面未達標。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間